Acute kidney injury
Drug research and approvals for acute kidney injury: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 205 studies of acute kidney injury are recruiting on ClinicalTrials.gov, and Health Canada has authorized 3 drug trials for it since 2013.
- Recruiting worldwide: 205
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
- Effects of Remote Ischemic Preconditioning at Different Time Phases in Patients Undergoing Heart Valve SurgeryNCT07888634 · Not applicable · Fujian Medical University Union Hospital · starts Mar 1, 2026
- Clinical Decision Support for SGLT2i After AKI in Type 2 DiabetesNCT07868666 · Not applicable · University of Minnesota · starts Nov 2, 2026
- Differentiating True Nephrotoxicity From Pseudo-nephrotoxicity: A Prospective Comparative Study of Vancomycin Plus…NCT07818265 · Not reported · King Faisal Specialist Hospital & Research Center · starts Sep 15, 2026
- Discovery and Validation of Biomarkers for CSA-AKI Risk PredictionNCT07811570 · Not reported · China National Center for Cardiovascular Diseases · starts Mar 1, 2026
- Early Endotoxin Burden Reduction With oXiris in Septic Shock Patients Requiring CRRTNCT07807410 · Not applicable · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · starts Aug 1, 2026
- Evaluation of the Association Between the VEXUS Score and Hemodynamic Status and the Occurrence of Acute Kidney Injury…NCT07805564 · Not reported · Hanoi Medical University · starts Jan 7, 2026
- Drug-induced Crystalluria in Sulfamethoxazole, High Dose Ciprofloxacin and High Dose AmoxicillinNCT07772752 · Not applicable · Universitair Ziekenhuis Brussel · starts Dec 8, 2025
- Perioperative Transcutaneous Fluorescence Detection of GFR Trajectory for the Early Prediction and Diagnosis of CSA-AKI.NCT07749417 · Not reported · China National Center for Cardiovascular Diseases · starts Jul 17, 2026
- Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal InjuryNCT07735182 · Not reported · First Affiliated Hospital of Zhejiang University · starts Feb 15, 2026
Approved 1
Phase 3 12 of 17
- TheophyllinePhosphodiesterase 4 inhibitor
- Epoetin betaErythropoietin receptor agonist
- Deferiprone
- FenoldopamDopamine D1 receptor agonist
- Nitric oxideSoluble guanylate cyclase activator
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- OxygenEssential for cellular homeostasis
- IrbesartanType-1 angiotensin II receptor antagonist
- Nitrous acid
- SpironolactoneMineralocorticoid receptor antagonist
- NesiritideAtrial natriuretic peptide receptor A agonist
- AcetylcysteineGlutathione precursor
Phase 2 12 of 27
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- ModimelanotideMelanocortin receptor 3 agonist
- CyclosporineCyclophilin A modulator
- Darbepoetin alfaErythropoietin receptor agonist
- AlprostadilProstanoid EP1 receptor agonist
- IohexolDiagnostic agent
- Insulin humanInsulin receptor agonist
- 2-mercaptoethanesulfonic acid
- CalcitriolVitamin D receptor agonist
- CalcifediolVitamin D receptor agonist
- AtorvastatinHMG-CoA reductase inhibitor
Phase 1 or earlier 12 of 13
- CXA-10
- IbuprofenCyclooxygenase inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- PravastatinHMG-CoA reductase inhibitor
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- Felbinac
- Intermedine
- RBT-9
- Stannic protoporfin
- IodixanolDiagnostic agent
- Niacinamide
How its trials ended
1,382 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 244 whose ending is known, 27% met their primary endpoint, 18% missed it and 55% stopped early.
- Completed, result not reported58542%
- Ongoing31123%
- Status unknown24218%
- Stopped: other or unclear806%
- Met its primary endpoint655%
- Missed its primary endpoint453%
- Stopped: enrollment or feasibility322%
- Stopped: lack of efficacy101%
- Stopped: sponsor or business decision6<1%
- Stopped: funding6<1%
| Oct 1, 2025 | A phase IIa, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy, safety, and tolerability of AZD4144 in participants with…AZD4144 | AstraZeneca Pharmaceuticals | Ongoing |
| Feb 12, 2025 | The prevention of nephrotoxin-induced acute kidney injury using cilastatin (PONTIAK): a phase 2b vanguard design, randomized, double-blind, placebo-controlled…Cilastatin | Governors of The University of Calgary | Ongoing |
| Sep 4, 2024 | A phase II, randomized, double-blind, placebo-controlled study of the efficacy and safety of GDC-8264 in preventing cardiac surgery-associated acute kidney…RO7288817 (GDC-8264) | Roche | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA